246 related articles for article (PubMed ID: 17274384)
41. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Chan E; Kwak EL; Hwang J; Heiskala M; de La Bourdonnaye G; Mita M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):701-9. PubMed ID: 25627002
[TBL] [Abstract][Full Text] [Related]
42. Second-line therapy in colorectal cancer.
Berlin J
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
44. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
45. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
[TBL] [Abstract][Full Text] [Related]
46. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Pan CX; Loehrer P; Seitz D; Helft P; Juliar B; Ansari R; Pletcher W; Vinson J; Cheng L; Sweeney C
Oncology; 2005; 69(1):63-70. PubMed ID: 16088234
[TBL] [Abstract][Full Text] [Related]
47. Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M
Lancet; 2000 Aug; 356(9229):566-7. PubMed ID: 10950238
[TBL] [Abstract][Full Text] [Related]
48. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
[No Abstract] [Full Text] [Related]
49. Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Tarver K; Conibear J; Raouf S
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):453-4. PubMed ID: 22472457
[No Abstract] [Full Text] [Related]
50. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Goldberg RM; Erlichman C
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
[TBL] [Abstract][Full Text] [Related]
51. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
Fujita K; Kubota Y; Ishida H; Sasaki Y
World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
[TBL] [Abstract][Full Text] [Related]
52. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
[No Abstract] [Full Text] [Related]
53. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
54. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Schmittel A; Jahnke K; Thiel E; Keilholz U
Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
[No Abstract] [Full Text] [Related]
55. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Ledermann JA; Leonard P; Seymour M
N Engl J Med; 2001 Jul; 345(2):145-6. PubMed ID: 11450667
[No Abstract] [Full Text] [Related]
56. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Fornaro L; Crea F; Masi G; Paolicchi E; Loupakis F; Graziano F; Salvatore L; Ronzoni M; Ricci V; Cremolini C; Schirripa M; Danesi R; Falcone A
Ann Oncol; 2012 May; 23(5):1370-1371. PubMed ID: 22383679
[No Abstract] [Full Text] [Related]
57. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN
Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062
[No Abstract] [Full Text] [Related]
58. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930
[TBL] [Abstract][Full Text] [Related]
59. The role of irinotecan in colorectal cancer.
Saltz LB
Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
[TBL] [Abstract][Full Text] [Related]
60. Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.
Gonzaga-López A; Muñoz-Rodriguez J; Ruiz-Casado A
Ann R Coll Surg Engl; 2017 Nov; 99(8):e225-e226. PubMed ID: 28768426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]